Literature DB >> 17066215

Realistic expectations for treatment success in Alzheimer's disease.

D S Geldmacher1, L Frolich, R S Doody, T Erkinjuntti, B Vellas, R W Jones, S Banerjee, P Lin, M Sano.   

Abstract

Alzheimer's disease (AD) is a progressive degenerative disease that warrants active management to delay or slow progression of its symptoms. The symptoms of AD encompass behavior and daily function as well as cognition, so clinicians should take a global view in the assessment of treatment success. Because there is currently no cure for AD, one cannot expect an initial cognitive improvement observed in the first few months of therapy to be sustained indefinitely. However, one should expect that the patient who is treated early and persistently with medication for AD will show less evidence of behavioral, functional, and cognitive deterioration over a period of time than one would expect in the absence of pharmacotherapy. Thus, treatment success includes not only short-term improvement of symptoms but also less decline over the long term. Determination of treatment success therefore also requires awareness of the typical progression of untreated AD. In this article we review the natural history of AD and evidence for the effectiveness of the treatments indicated for AD: donepezil, galantamine, rivastigmine, and memantine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17066215

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  26 in total

1.  The art of sharing the diagnosis and management of Alzheimer's disease with patients and caregivers: recommendations of an expert consensus panel.

Authors:  George T Grossberg; Daniel D Christensen; Patrick A Griffith; Diana R Kerwin; Gail Hunt; Eric J Hall
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

3.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Authors:  Martin R Farlow; Stephen Salloway; Pierre N Tariot; Jane Yardley; Margaret L Moline; Qin Wang; Elimor Brand-Schieber; Heng Zou; Timothy Hsu; Andrew Satlin
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

Review 4.  The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.

Authors:  William James Deardorff; Eliahu Feen; George T Grossberg
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 5.  Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

Authors:  Paul S Aisen; Jeffrey Cummings; Lon S Schneider
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

6.  Implications of the Impact Survey for payors across Europe.

Authors:  F Forette; A Padovani; K Berthet; S Knox
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

7.  Assessing physician attitudes and perceptions of Alzheimer's disease across Europe.

Authors:  P Martinez-Lage; L Frolich; S Knox; K Berthet
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

8.  Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.

Authors:  David Wilkinson; Rachel Schindler; Elias Schwam; Gunhild Waldemar; Roy W Jones; Serge Gauthier; Oscar L Lopez; Jeffrey Cummings; Yikang Xu; Howard H Feldman
Journal:  Dement Geriatr Cogn Disord       Date:  2009-09-25       Impact factor: 2.959

9.  Alzheimer's disease dietary supplements in websites.

Authors:  Nicole Palmour; Brandy L Vanderbyl; Emma Zimmerman; Serge Gauthier; Eric Racine
Journal:  HEC Forum       Date:  2013-12

10.  Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.

Authors:  Susan M Abughosh; Stephen J Kogut
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.